Prognostic factors for survival in patients with advanced intrahepatic cholangiocarcinoma treated with gemcitabine plus cisplatin as first line tre...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter U. Ishimoto
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors U. Ishimoto1, M. Sasaki2, S. Kondo2, Y. Sakamoto2, C. Morizane2, H. Ueno2, T. Okusaka2
  • 1National Cancer Center Hospital, Chuo-ku, Japan, /
  • 2Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan, /

Abstract

Intrahepatic cholangiocarcinoma is about 4% in hepatic malignancy and is associated with a poor prognosis. First line treatment with gemcitabine plus cisplatin (GC) increases overall survival in patients (pts) with advanced biliary tract cancer compared with gemcitabine (Valle J et al N Engl J Med, 2010). Prognostic factors in pts with unresectable or recurrent intrahepatic cholangiocarcinoma receiving palliative chemotherapy have not been well established. We aimed to evaluate prognostic factors in unresectable or recurrent intrahepatic cholangiocarcinoma receiving GC as first line treatment.